COMP <GO>
LGND vs JNJ // NET PROFIT MARGIN
Ligand Pharmaceuticals Incorporated (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: LGND 5
— JNJ 8
▲ NET PROFIT MARGIN LEADER: LGND
LAST: $322.75 (+1.71%) • MKT CAP: $6.33B
net-margins
46.40%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
net-margins
28.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LGND VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LGND | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.00% | 25.50% | -22.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 18.5x | +76.50 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 0.77% | 2.97% | -2.20 | JNJ | /fcf-yield <GO> |
| Operating Margin | 15.30% | 34.70% | -19.40 | JNJ | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 46.40% | 28.50% | +17.90 | LGND | /net-margins <GO> |
| Revenue Growth (YoY) | 60.40% | 6.00% | +54.40 | LGND | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.40 | 5.59 | +2.81 | LGND | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.20% | -0.10 | LGND | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.4 | 60.4 | +3.04 | LGND | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 1.08 | -0.01 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 42.7x | 23.0x | +19.70 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.33B | $662.49B | -$656.17B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LGND REV | JNJ REV | LGND GROSS % | JNJ GROSS % | LGND FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $268.1M | $94.19B | 44.0% | 67.9% | $48.9M | $19.70B |
| FY 2024 | $167.1M | $88.82B | 44.0% | 69.1% | $95.2M | $19.84B |
| FY 2023 | $131.3M | $85.16B | 44.0% | 44.0% | $43.7M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LGND // BETA 1.07
JNJ // BETA 1.08